Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives

Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodenburg, RJ, Eskens, FALM
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526773/
https://www.ncbi.nlm.nih.gov/pubmed/31190952
http://dx.doi.org/10.2147/IJNRD.S169056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6526773/
https://www.ncbi.nlm.nih.gov/pubmed/31190952
http://dx.doi.org/10.2147/IJNRD.S169056

Ejemplares similares